Cabozantinib S-Malate in Treating Patients With Neuroendocrine TumorsResearch Question:
How well does cabozantinib S-malate work compared with placebo in treating patients
with neuroendocrine tumors that have spread after previous treatment with everolimus?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This randomized phase III trial studies cabozantinib S-malate to see how well it works
compared with placebo in treating patients with neuroendocrine tumors that have spread
to nearby tissues or lymph nodes, have spread to other places in the body, or cannot
be removed by surgery after previous treatment with everolimus. Cabozantinib S-malate
is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific
tyrosine kinase receptors, that when blocked, may slow tumor growth.
Study Reference #: CGIP19127
Lead Researcher (Principal Investigator)
Lead Researcher: Aram Hezel
Study Contact InformationStudy Coordinator: Chris LeFeber
Phone: (585) 275-0407
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search